Thus, some reports indicate that Gal-1 induces resistance to specific treatments in certain malignancies, such as kinase inhibitors (sorafenib) in HCC or cisplatin in cervical squamous cell carcinoma and HCC [87,88,89]. The gene discussed is LGALS1; the disease is hepatocellular carcinoma.